Latest Conference Articles

Marcelo V. Negrao, MD, discusses updated efficacy and safety data for first-line olomorasib plus chemoimmunotherapy in KRAS G12C–mutant NSCLC.

Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.

Lauren Banks, MD, PhD, discusses feasibility findings for lifileucel in select metastatic sarcomas and next steps with the phase 2 SARATOGA trial.

Justin Moser, MD, discusses safety and activity of the IL-2 prodrug WTX-124 alone or with pembrolizumab in immune-sensitive solid tumors.

A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.

Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.

A post hoc analysis of SPEARHEAD-1 found that MAGE-A4 H-score was independently tied to response and progression-free survival, whereas baseline tumor burden was tied to overall survival.

The IL-12–expressing self-replicating mRNA STX-001 showed a favorable therapeutic window at 100 µg, with regression in both injected and non-injected lesions.

Most of the survival time accrued with RP1 plus nivolumab in the IGNYTE trial was spent in good health among patients with advanced melanoma after anti–PD-1 therapy.

VET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.

Steven Isakoff, MD, PhD, MMSc, discusses data for invikafusp alfa plus sacituzumab govitecan in advanced HR-positive or triple-negative breast cancer.

Laura Graham, MD, discusses phase 1 safety and PSA response data for JNJ-87189401 plus pasritamig in metastatic castration-resistant prostate cancer.

IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.

VGX-3100 met its composite primary end point in the phase 3 HPV-303CHN trial, supporting a nonsurgical treatment approach for HPV-16/18–associated cervical HSIL.

EVX-01 plus pembrolizumab generated sustained neoantigen-specific T-cell responses in advanced melanoma.

IDP-023 plus isatuximab was tolerable and generated responses in heavily pretreated relapsed/refractory multiple myeloma.

Yana Najjar, MD, discusses phase 1/1b STEALTH-001 data for the oncolytic virus VET3-TGI in advanced solid tumors, including cutaneous cancers.

Daniel W. Lee, III, MD, discusses a case study of polatuzumab vedotin/glofitamab and CD19 CAR T-cell therapy in a child with refractory Burkitt lymphoma.

David VanderWeele, MD, PhD, reviews where lutetium Lu 177 vipivotide tetraxetan fits across metastatic prostate cancer, how to select and manage patients, and the new radionuclides, targeting molecules, and antigens under investigation.

Longer follow-up of CAPItello-281 showed capivasertib plus abiraterone extended survival in PTEN-deficient hormone-sensitive prostate cancer.

Joshua J. Meeks, MD, PhD, explains how enfortumab vedotin plus pembrolizumab is reshaping organ preservation in MIBC.

Suzanne B. Merrill, MD, discusses patient selection and toxicity considerations for BCG plus durvalumab in BCG-naive, high-risk NMIBC.

Benjamin Garmezy, MD, discusses how biomarkers, toxicity, and patient preferences guide treatment intensification in advanced prostate cancer.

Katie S. Murray, DO, discusses how efficacy, toxicity, patient preferences, and treatment logistics guide BCG-unresponsive NMIBC care.

Vignesh T. Packiam, MD, reviews why improved BCG outcomes support its first-line use, with gemcitabine/docetaxel as a BCG-sparing option.

Experts break down key melanoma data and trends from the 2026 ESMO Congress.

Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.

Durvalumab plus BCG is now an approved first-line option for high-risk NMIBC, but better BCG delivery and biomarker-guided selection should shape its use.

Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.

Lutetium Lu 177 vipivotide tetraxetan showed a median overall survival of 13.1 months in the French PSMA-REACH mCRPC cohort.